Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Pharmaxis Ltd ( (AU:SNT) ) has issued an announcement.
Syntara Limited announced positive interim results from its Phase 2 clinical trial of SNT-5505 for myelofibrosis, demonstrating significant improvements in symptom relief and spleen volume reduction. This promising outcome, presented at the ASH conference, has the potential to change current treatment paradigms and has facilitated a successful capital raising of A$15 million to further fund clinical trials and operational costs.
More about Pharmaxis Ltd
Syntara Limited is a clinical stage drug development company operating in the biotechnology industry. Its primary focus is on developing medications for conditions such as myelofibrosis, myelodysplastic syndrome, iRBD/Parkinson’s disease, and scar therapies, with a notable emphasis on addressing unmet medical needs.
YTD Price Performance: -11.25%
Average Trading Volume: 4,998,478
Technical Sentiment Consensus Rating: Hold
Current Market Cap: A$112.1M
Find detailed analytics on SNT stock on TipRanks’ Stock Analysis page.
